JACC Vol. 57, No. 11, 2011 Fuster et al. e103March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelines 184.108.40.206. IMPLICATIONS OF THE RHYTHM-CONTROL 220.127.116.11.2. PROCAINAMIDE .............e147 VERSUS RATE-CONTROL STUDIES ...........e126 18.104.22.168.3. BETA BLOCKERS ............e147 8.1.3. Rate Control During Atrial 22.214.171.124.4. NONDIHYDROPYRIDINE CALCIUM Fibrillation (UPDATED) . . . . . . . . . . . . . . .e126 CHANNEL ANTAGONISTS 126.96.36.199. PHARMACOLOGICAL RATE CONTROL DURING (VERAPAMIL AND DILTIAZEM) ....e148 ATRIAL FIBRILLATION .....................e127 188.8.131.52.5. DIGOXIN....................e148 184.108.40.206.1. BETA BLOCKERS ............e127 220.127.116.11.6. DISOPYRAMIDE .............e148 18.104.22.168.2. NONDIHYDROPYRIDINE CALCIUM 22.214.171.124.7. SOTALOL ...................e148 CHANNEL ANTAGONISTS ......e129 8.1.6. Pharmacological Agents to Maintain 126.96.36.199.3. DIGOXIN....................e129 188.8.131.52.4. ANTIARRHYTHMIC AGENTS ...e129 Sinus Rhythm. . . . . . . . . . . . . . . . . . . . . . . . .e148 184.108.40.206. AGENTS WITH PROVEN EFFICACY TO 220.127.116.11.5. COMBINATION THERAPY ......e129 MAINTAIN SINUS RHYTHM .................e148 18.104.22.168.6. SPECIAL CONSIDERATIONS IN 22.214.171.124.1. AMIODARONE ...............e149 PATIENTS WITH THE WOLFF- 126.96.36.199.2. BETA BLOCKERS ............e149 PARKINSON-WHITE (WPW) 188.8.131.52.3. DOFETILIDE .................e150 SYNDROME .................e129 184.108.40.206.4. DISOPYRAMIDE .............e150 220.127.116.11. PHARMACOLOGICAL THERAPY TO CONTROL 18.104.22.168.5. FLECAINIDE .................e150 HEART RATE IN PATIENTS WITH BOTH ATRIAL 22.214.171.124.6. PROPAFENONE ..............e150 FIBRILLATION AND ATRIAL FLUTTER ..........e130 126.96.36.199.7. SOTALOL ...................e150 188.8.131.52. REGULATION OF ATRIOVENTRICULAR NODAL 184.108.40.206. DRUGS WITH UNPROVEN EFFICACY OR NO CONDUCTION BY PACING ..................e130 LONGER RECOMMENDED ..................e151 220.127.116.11. AV NODAL ABLATION ......................e130 18.104.22.168.1. DIGOXIN....................e151 8.1.4. Preventing Thromboembolism . . . . . . . . . . .e131 22.214.171.124. RISK STRATIFICATION .....................e132 126.96.36.199.2. PROCAINAMIDE .............e151 188.8.131.52.1. EPIDEMIOLOGICAL DATA......e132 184.108.40.206.3. QUINIDINE ..................e151 220.127.116.11.2. ECHOCARDIOGRAPHY AND 18.104.22.168.4. VERAPAMIL AND DILTIAZEM ....e151 RISK STRATIFICATION ........e133 8.1.7. Out-of-Hospital Initiation of Antiarrhythmic 22.214.171.124.3. THERAPEUTIC IMPLICATIONS ....e134 Drugs in Patients With Atrial Fibrillation . . . .e151 126.96.36.199. ANTITHROMBOTIC STRATEGIES FOR 8.1.8. Drugs Under Development . . . . . . . . . . . . . .e154 PREVENTION OF ISCHEMIC STROKE AND 188.8.131.52. ATRIOSELECTIVE AGENTS ..................e154 SYSTEMIC EMBOLISM .....................e135 184.108.40.206. NONSELECTIVE ION 220.127.116.11.1. ANTICOAGULATION WITH VITAMIN K CHANNEL–BLOCKING DRUGS ...............e154 ANTAGONIST AGENTS ..........e136 18.104.22.168. RECOMMENDATIONS FOR DRONEDARONE FOR 22.214.171.124.2. ASPIRIN FOR ANTITHROMBOTIC THE PREVENTION OF RECURRENT ATRIAL THERAPY IN PATIENTS WITH FIBRILLATION (NEW SECTION) ...............e154 ATRIAL FIBRILLATION..........e137 8.2. Direct-Current Cardioversion of Atrial 126.96.36.199.3. OTHER ANTIPLATELET AGENTS Fibrillation and Flutter . . . . . . . . . . . . . . . . . . . . . .e154 FOR ANTITHROMBOTIC 8.2.1. Terminology . . . . . . . . . . . . . . . . . . . . . . . . . .e155 THERAPY IN PATIENTS WITH 8.2.2. Technical Aspects . . . . . . . . . . . . . . . . . . . . .e155 ATRIAL FIBRILLATION.........e138 8.2.3. Procedural Aspects . . . . . . . . . . . . . . . . . . . . .e155 188.8.131.52.4. COMBINING ANTICOAGULANT 8.2.4. Direct-Current Cardioversion in Patients AND PLATELET-INHIBITOR THERAPY (UPDATED) .........e140 With Implanted Pacemakers 184.108.40.206.5. EMERGING AND INVESTIGATIONAL and Deﬁbrillators . . . . . . . . . . . . . . . . . . . . . . .e156 ANTITHROMBOTIC AGENTS 8.2.5. Risks and Complications of Direct-Current (UPDATED) ..................e141 Cardioversion of Atrial Fibrillation . . . . . . . .e156 220.127.116.11.6. INTERRUPTION OF ANTICOAGULATION 8.2.6. Pharmacological Enhancement of FOR DIAGNOSTIC OR THERAPEUTIC Direct-Current Cardioversion . . . . . . . . . . . .e156 18.104.22.168. AMIODARONE ............................e157 PROCEDURES ................e141 22.214.171.124. BETA-ADRENERGIC ANTAGONISTS...........e158 126.96.36.199. NONPHARMACOLOGICAL APPROACHES TO 188.8.131.52. NONDIHYDROPYRIDINE CALCIUM PREVENTION OF THROMBOEMBOLISM CHANNEL ANTAGONISTS ...................e158 (UPDATED) ...............................e142 184.108.40.206. QUINIDINE ...............................e158 8.1.5. Cardioversion of Atrial Fibrillation . . . . . . . .e142 220.127.116.11. BASIS FOR CARDIOVERSION OF 18.104.22.168. TYPE IC ANTIARRHYTHMIC AGENTS .........e158 .....................e142 ATRIAL FIBRILLATION 22.214.171.124. TYPE III ANTIARRHYTHMIC AGENTS ..........e158 126.96.36.199. METHODS OF CARDIOVERSION .............e142 8.2.7. Prevention of Thromboembolism in 188.8.131.52. PHARMACOLOGICAL CARDIOVERSION .......e143 Patients With Atrial Fibrillation 184.108.40.206. AGENTS WITH PROVEN EFFICACY FOR Undergoing Cardioversion . . . . . . . . . . . . . . .e158 CARDIOVERSION OF ATRIAL FIBRILLATION .....e144 8.3. Maintenance of Sinus Rhythm. . . . . . . . . . . . . . .e160 220.127.116.11.1. AMIODARONE ...............e144 8.3.1. Pharmacological Therapy (UPDATED) . . .e160 18.104.22.168.2. DOFETILIDE .................e144 22.214.171.124. GOALS OF TREATMENT ....................e160 126.96.36.199.3. FLECAINIDE .................e144 188.8.131.52. ENDPOINTS IN ANTIARRHYTHMIC 184.108.40.206.4. IBUTILIDE ..................e145 DRUG STUDIES ...........................e160 220.127.116.11.5. PROPAFENONE ..............e146 18.104.22.168. PREDICTORS OF RECURRENT AF ............e161 22.214.171.124. LESS EFFECTIVE OR INCOMPLETELY STUDIED 126.96.36.199. CATHETER-BASED ABLATION THERAPY FOR AGENTS FOR CARDIOVERSION OF ATRIAL FIBRILLATION (NEW SECTION) .......e161 ATRIAL FIBRILLATION .....................e146 8.3.2. General Approach to Antiarrhythmic 188.8.131.52.1. QUINIDINE ..................e146 Drug Therapy . . . . . . . . . . . . . . . . . . . . . . . . .e161
e104 Fuster et al. JACC Vol. 57, No. 11, 2011 ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98 8.3.3. Selection of Antiarrhythmic Agents in expert analysis of the available data documenting absolute and Patients With Cardiac Diseases . . . . . . . . . .e162 relative beneﬁts and risks of those procedures and therapies can 184.108.40.206. HEART FAILURE ..........................e162 220.127.116.11. CORONARY ARTERY DISEASE ..............e162 produce helpful guidelines that improve the effectiveness of care, 18.104.22.168. HYPERTENSIVE HEART DISEASE ............e162 optimize patient outcomes, and favorably affect the overall cost 8.3.4. Nonpharmacological Therapy for of care by focusing resources on the most effective strategies. Atrial Fibrillation . . . . . . . . . . . . . . . . . . . . . .e163 The American College of Cardiology Foundation (ACCF) 22.214.171.124. SURGICAL ABLATION ......................e163 and the American Heart Association (AHA) have jointly en- 126.96.36.199. CATHETER ABLATION ......................e163 188.8.131.52.1. COMPLICATIONS OF gaged in the production of such guidelines in the area of CATHETER-BASED ABLATION ...e164 cardiovascular disease since 1980. The ACC/AHA Task Force 184.108.40.206.2. FUTURE DIRECTIONS IN on Practice Guidelines, whose charge is to develop, update, or CATHETER-BASED ABLATION revise practice guidelines for important cardiovascular diseases THERAPY FOR ATRIAL and procedures, directs this effort. The Task Force is pleased to FIBRILLATION ...............e164 have this guideline developed in conjunction with the European 220.127.116.11. SUPPRESSION OF ATRIAL FIBRILLATION Society of Cardiology (ESC). Writing committees are charged THROUGH PACING ........................e165 18.104.22.168. INTERNAL ATRIAL DEFIBRILLATORS .........e165 with the task of performing an assessment of the evidence and acting as an independent group of authors to develop or update 8.4. Special Considerations . . . . . . . . . . . . . . . . . . . . .e166 written recommendations for clinical practice. 8.4.1. Postoperative AF . . . . . . . . . . . . . . . . . . . . . .e166 22.214.171.124. CLINICAL AND Experts in the subject under consideration have been selected PATHOPHYSIOLOGICAL CORRELATES ........e166 from all 3 organizations to examine subject-speciﬁc data and 126.96.36.199. PREVENTION OF POSTOPERATIVE AF ........e167 write guidelines. The process includes additional representatives 188.8.131.52. TREATMENT OF POSTOPERATIVE AF .........e167 from other medical practitioner and specialty groups when 8.4.2. Acute Myocardial Infarction . . . . . . . . . . . . .e168 appropriate. Writing committees are speciﬁcally charged to 8.4.3. Wolff-Parkinson White (WPW) Preexcitation Syndromes . . . . . . . . . . . . . . . .e168 perform a formal literature review, weigh the strength of 8.4.4. Hyperthyroidism . . . . . . . . . . . . . . . . . . . . . .e169 evidence for or against a particular treatment or procedure, and 8.4.5. Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . .e170 include estimates of expected health outcomes where data exist. 8.4.6. Hypertrophic Cardiomyopathy . . . . . . . . . . .e170 Patient-speciﬁc modiﬁers, comorbidities, and issues of patient 8.4.7. Pulmonary Diseases . . . . . . . . . . . . . . . . . . . .e171 preference that might inﬂuence the choice of particular tests or 8.5. Primary Prevention . . . . . . . . . . . . . . . . . . . . . . . . .e171 therapies are considered as well as frequency of follow-up and9. Proposed Management Strategies. . . . . . . . . . . . .e172 cost-effectiveness. When available, information from studies on cost will be considered; however, review of data on efﬁcacy and 9.1. Overview of Algorithms for Management of clinical outcomes will constitute the primary basis for preparing Patients With Atrial Fibrillation . . . . . . . . . . . . .e172 recommendations in these guidelines. 9.1.1. Newly Discovered Atrial Fibrillation . . . . . .e172 The ACC/AHA Task Force on Practice Guidelines and the 9.1.2. Recurrent Paroxysmal Atrial Fibrillation . . .e172 ESC Committee for Practice Guidelines make every effort to 9.1.3. Recurrent Persistent Atrial Fibrillation . . . . .e173 9.1.4. Permanent Atrial Fibrillation . . . . . . . . . . . .e173 avoid any actual, potential, or perceived conﬂict of interest that might arise as a result of an outside relationship or personalAPPENDIX I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e174 interest of the writing committee. Speciﬁcally, all members of the Writing Committee and peer reviewers of the document areAPPENDIX II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e175 asked to provide disclosure statements of all such relationships that might be perceived as real or potential conﬂicts of interest.APPENDIX III. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e177 Writing committee members are also strongly encouraged to declare a previous relationship with industry that might beAPPENDIX IV (NEW SECTION) . . . . . . . . . . . . . . . . . . . .e178 perceived as relevant to guideline development. If a writing committee member develops a new relationship with industry during their tenure, they are required to notify guideline staff inReferences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e178 writing. The continued participation of the writing committee member will be reviewed. These statements are reviewed by thePreamble (UPDATED) For new or parent Task Force, reported orally to all members of the writing committee at each meeting, and updated and reviewed by theupdated text, view the 2011 Focused writing committee as changes occur. Please refer to the meth-Update and the 2011 Focused Update odology manuals for further description of the policies used inon Dabigatran. Text supporting guideline development, including relationships with industry,unchanged recommendations has not available online at the ACC, AHA, and ESC World Widebeen updated. Web sites (http://www.acc.org/clinical/manual/manual_ introltr.htm, http://circ.ahajournals.org/manual/, and http://It is important that the medical profession play a signiﬁcant role www.escardio.org/knowledge/guidelines/Rules/). Please seein critically evaluating the use of diagnostic procedures and Appendix I for author relationships with industry and Appen-therapies as they are introduced and tested in the detection, dix II for peer reviewer relationships with industry that aremanagement, or prevention of disease states. Rigorous and pertinent to these guidelines.
JACC Vol. 57, No. 11, 2011 Fuster et al. e105March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelines These practice guidelines are intended to assist healthcare Association (EHRA) and the Heart Rhythm Society (HRS).providers in clinical decision making by describing a range of This document was reviewed by 2 ofﬁcial reviewers nomi-generally acceptable approaches for the diagnosis, manage- nated by the ACC, 2 ofﬁcial reviewers nominated by thement, and prevention of speciﬁc diseases and conditions. AHA, and 2 ofﬁcial reviewers nominated by the ESC, as wellThese guidelines attempt to deﬁne practices that meet the as by the ACCF Clinical Electrophysiology Committee, theneeds of most patients in most circumstances. These guide- AHA ECG and Arrhythmias Committee, the AHA Strokeline recommendations reﬂect a consensus of expert opinion Review Committee, EHRA, HRS, and numerous additionalafter a thorough review of the available, current scientiﬁc content reviewers nominated by the writing committee. Theevidence and are intended to improve patient care. If these document was approved for publication by the governingguidelines are used as the basis for regulatory/payer deci- bodies of the ACC, AHA, and ESC and ofﬁcially endorsed bysions, the ultimate goal is quality of care and serving the the EHRA and the HRS.patient’s best interests. The ultimate judgment regarding care The ACC/AHA/ESC Writing Committee to Revise theof a particular patient must be made by the healthcare 2001 Guidelines for the Management of Patients With Atrialprovider and the patient in light of all of the circumstances Fibrillation conducted a comprehensive review of the rele-presented by that patient. There are circumstances in which vant literature from 2001 to 2006. Literature searches weredeviations from these guidelines are appropriate. conducted in the following databases: PubMed/MEDLINE The guidelines will be reviewed annually by the ACC/AHA and the Cochrane Library (including the Cochrane DatabaseTask Force on Practice Guidelines and the ESC Committee for of Systematic Reviews and the Cochrane Controlled TrialsPractice Guidelines and will be considered current unless they Registry). Searches focused on English-language sources andare updated, revised, or sunsetted and withdrawn from distribu- studies in human subjects. Articles related to animal experi-tion. The executive summary and recommendations are pub- mentation were cited when the information was important tolished in the August 15, 2006, issues of the Journal of the understanding pathophysiological concepts pertinent to pa-American College of Cardiology and Circulation and the August tient management and comparable data were not available16, 2006, issue of the European Heart Journal. The full-text from human studies. Major search terms included atrialguidelines are published in the August 15, 2006, issues of the ﬁbrillation, age, atrial remodeling, atrioventricular conduc-Journal of the American College of Cardiology and Circulation tion, atrioventricular node, cardioversion, classiﬁcation,and the September 2006 issue of Europace, as well as posted on clinical trial, complications, concealed conduction, cost-the ACC (www.acc.org), AHA (www.americanheart.org), andESC (www.escardio.org) World Wide Web sites. Copies of the effectiveness, deﬁbrillator, demographics, epidemiology, ex-full-text guidelines and the executive summary are available perimental, heart failure (HF), hemodynamics, human, hy-from all 3 organizations. perthyroidism, hypothyroidism, meta-analysis, myocardial infarction, pharmacology, postoperative, pregnancy, pulmo- Sidney C. Smith Jr, MD, FACC, FAHA, FESC, Chair, nary disease, quality of life, rate control, rhythm control, ACC/AHA Task Force on Practice Guidelines risks, sinus rhythm, symptoms, and tachycardia-mediated Silvia G. Priori, MD, PhD, FESC, Chair, cardiomyopathy.The complete list of search terms is beyond ESC Committee for Practice Guidelines the scope of this section. Classiﬁcation of Recommendations and Level of Evidence1. Introduction are expressed in the ACC/AHA/ESC format as follows and described in Table 1. Recommendations are evidence based and derived primarily from published data.1.1. Organization of Committee andEvidence Review (UPDATED) Classiﬁcation of RecommendationsFor new or updated text, view the 2011 • Class I: Conditions for which there is evidence and/orFocused Update and the 2011 Update on general agreement that a given procedure/therapy is ben-Dabigatran. Text supporting unchanged eﬁcial, useful, and effective.recommendations has not been updated. • Class II: Conditions for which there is conﬂicting evidenceAtrial ﬁbrillation (AF) is the most common sustained cardiac and/or a divergence of opinion about the usefulness/rhythm disturbance, increasing in prevalence with age. AF is efﬁcacy of performing the procedure/therapy.often associated with structural heart disease, although a X Class IIa: Weight of evidence/opinion is in favor ofsubstantial proportion of patients with AF have no detectable usefulness/efﬁcacy.heart disease. Hemodynamic impairment and thromboem- X Class IIb: Usefulness/efﬁcacy is less well established bybolic events related to AF result in signiﬁcant morbidity, evidence/opinion.mortality, and cost. Accordingly, the American College of • Class III: Conditions for which there is evidence and/orCardiology (ACC), the American Heart Association (AHA), general agreement that a procedure/therapy is not useful orand the European Society of Cardiology (ESC) created a effective and in some cases may be harmful.committee to establish guidelines for optimum managementof this frequent and complex arrhythmia. Level of Evidence The committee was composed of members representing the The weight of evidence was ranked from highest (A) toACC, AHA, and ESC, as well as the European Heart Rhythm lowest (C), as follows:
e106 Fuster et al. JACC Vol. 57, No. 11, 2011 ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98TABLE 1. Applying Classiﬁcation of Recommendations and Level of Evidence† (UPDATED) (see the 2011 Focused Update and the2011 Focused Update on Dabigatran) *Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as gender, age, history of diabetes, history of priormyocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak.Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there maybe a very clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guidelinerecommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart fromthe rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this willincrease readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.• Level of Evidence A: Data derived from multiple random- potentially dangerous arrhythmia is then reviewed. This ized clinical trials or meta-analyses. includes prevention of AF, control of heart rate, prevention of• Level of Evidence B: Data derived from a single random- thromboembolism, and conversion to and maintenance of ized trial, or nonrandomized studies. sinus rhythm. The treatment algorithms include pharmaco-• Level of Evidence C: Only consensus opinion of experts, logical and nonpharmacological antiarrhythmic approaches, case studies, or standard-of-care. as well as antithrombotic strategies most appropriate for particular clinical conditions. Overall, this is a consensus1.2. Contents of These Guidelines document that attempts to reconcile evidence and opinionThese guidelines ﬁrst present a comprehensive review of the from both sides of the Atlantic Ocean. The pharmacologicallatest information about the deﬁnition, classiﬁcation, epide- and nonpharmacological antiarrhythmic approaches may in-miology, pathophysiological mechanisms, and clinical char- clude some drugs and devices that do not have the approvalacteristics of AF. The management of this complex and of all government regulatory agencies. Additional informa-
JACC Vol. 57, No. 11, 2011 Fuster et al. e107March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelinestion may be obtained from the package inserts when the drug P waves by rapid oscillations or ﬁbrillatory waves that vary inor device has been approved for the stated indication. amplitude, shape, and timing, associated with an irregular, Because atrial ﬂutter can precede or coexist with AF, frequently rapid ventricular response when atrioventricularspecial consideration is given to this arrhythmia in each (AV) conduction is intact (2) (Fig. 1). The ventricularsection. There are important differences in the mechanisms of response to AF depends on electrophysiological (EP) prop-AF and atrial ﬂutter, and the body of evidence available to erties of the AV node and other conducting tissues, the levelsupport therapeutic recommendations is distinct for the 2 of vagal and sympathetic tone, the presence or absence ofarrhythmias. Atrial ﬂutter is not addressed comprehensively accessory conduction pathways, and the action of drugs (3).in these guidelines but is addressed in the ACC/AHA/ESC Regular cardiac cycles (R-R intervals) are possible in theGuidelines on the Management of Patients with Supraven- presence of AV block or ventricular or AV junctionaltricular Arrhythmias (1). tachycardia. In patients with implanted pacemakers, diagno- sis of AF may require temporary inhibition of the pacemaker1.3. Changes Since the Initial Publication of to expose atrial ﬁbrillatory activity (4). A rapid, irregular,These Guidelines in 2001 sustained, wide-QRS-complex tachycardia strongly suggestsIn developing this revision of the guidelines, the Writing AF with conduction over an accessory pathway or AF withCommittee considered evidence published since 2001 and underlying bundle-branch block. Extremely rapid rates (overdrafted revised recommendations where appropriate to incor- 200 beats per minute) suggest the presence of an accessoryporate results from major clinical trials such as those that pathway or ventricular tachycardia.compared rhythm-control and rate-control approaches tolong-term management. The text has been reorganized to 2.2. Related Arrhythmiasreﬂect the implications for patient care, beginning with AF may occur in isolation or in association with otherrecognition of AF and its pathogenesis and the general arrhythmias, most commonly atrial ﬂutter or atrial tachycar-priorities of rate control, prevention of thromboembolism, dia. Atrial ﬂutter may arise during treatment with antiarrhyth-and methods available for use in selected patients to correct mic agents prescribed to prevent recurrent AF. Atrial ﬂutter inthe arrhythmia and maintain normal sinus rhythm. Advances the typical form is characterized by a saw-tooth pattern ofin catheter-based ablation technologies have been incorpo- regular atrial activation called ﬂutter (ƒ) waves on the ECG,rated into expanded sections and recommendations, with the particularly visible in leads II, III, aVF, and V1 (Fig. 2). In therecognition that that such vital details as patient selection, untreated state, the atrial rate in atrial ﬂutter typically rangesoptimum catheter positioning, absolute rates of treatment from 240 to 320 beats per minute, with ƒ waves inverted insuccess, and the frequency of complications remain incom- ECG leads II, III, and aVF and upright in lead V1. Thepletely deﬁned. Sections on drug therapy have been con- direction of activation in the right atrium (RA) may bedensed and conﬁned to human studies with compounds that reversed, resulting in ƒ waves that are upright in leads II, III,have been approved for clinical use in North America and/or and aVF and inverted in lead V1. Atrial ﬂutter commonlyEurope. Accumulating evidence from clinical studies on the occurs with 2:1 AV block, resulting in a regular or irregularemerging role of angiotensin inhibition to reduce the occur- ventricular rate of 120 to 160 beats per minute (mostrence and complications of AF and information on ap- characteristically about 150 beats per minute). Atrial ﬂutterproaches to the primary prevention of AF are addressed may degenerate into AF and AF may convert to atrial ﬂutter.comprehensively in the text, as these may evolve further in The ECG pattern may ﬂuctuate between atrial ﬂutter and AF,the years ahead to form the basis for recommendations reﬂecting changing activation of the atria. Atrial ﬂutter isaffecting patient care. Finally, data on speciﬁc aspects of usually readily distinguished from AF, but when atrial activ-management of patients who are prone to develop AF in ity is prominent on the ECG in more than 1 lead, AF may bespecial circumstances have become more robust, allowing misdiagnosed as atrial ﬂutter (5).formulation of recommendations based on a higher level of Focal atrial tachycardias, AV reentrant tachycardias, andevidence than in the ﬁrst edition of these guidelines. An AV nodal reentrant tachycardias may also trigger AF. In otherexample is the completion of a relatively large randomized atrial tachycardias, P waves may be readily identiﬁed and aretrial addressing prophylactic administration of antiarrhythmic separated by an isoelectric baseline in 1 or more ECG leads.medication for patients undergoing cardiac surgery. In devel- The morphology of the P waves may help localize the originoping the updated recommendations, every effort was made to of the tachycardias.maintain consistency with other ACC/AHA and ESC practiceguidelines addressing, for example, the management of pa- 3. Classiﬁcationtients undergoing myocardial revascularization procedures. Various classiﬁcation systems have been proposed for AF.2. Deﬁnition One is based on the ECG presentation (2– 4). Another is based on epicardial (6) or endocavitary recordings or non-2.1. Atrial Fibrillation contact mapping of atrial electrical activity. Several clinicalAF is a supraventricular tachyarrhythmia characterized by classiﬁcation schemes have also been proposed, but noneuncoordinated atrial activation with consequent deterioration fully accounts for all aspects of AF (7–10). To be clinicallyof atrial mechanical function. On the electrocardiogram useful, a classiﬁcation system must be based on a sufﬁcient(ECG), AF is characterized by the replacement of consistent number of features and carry speciﬁc therapeutic implications.
e108 Fuster et al. JACC Vol. 57, No. 11, 2011 ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98Figure 1. Electrocardiogram showing atrial ﬁbrillation with a controlled rate of ventricular response. P waves are replaced by ﬁbrillatorywaves and the ventricular response is completely irregular. Assorted labels have been used to describe the pattern of recommended in this document represents a consensus drivenAF, including acute, chronic, paroxysmal, intermittent, con- by a desire for simplicity and clinical relevance.stant, persistent, and permanent, but the vagaries of deﬁni- The clinician should distinguish a ﬁrst-detected episode oftions make it difﬁcult to compare studies of AF or the AF, whether or not it is symptomatic or self-limited, recog-effectiveness of therapeutic strategies based on these desig- nizing that there may be uncertainty about the duration of thenations. Although the pattern of the arrhythmia can change episode and about previous undetected episodes (Fig. 3).over time, it may be of clinical value to characterize the When a patient has had 2 or more episodes, AF is consideredarrhythmia at a given moment. The classiﬁcation scheme recurrent. If the arrhythmia terminates spontaneously, recur-Figure 2. Electrocardiogram showing typical atrial ﬂutter with variable atrioventricular conduction. Note the saw-tooth pattern, F waves,particularly visible in leads II, III, and aVF, without an isoelectric baseline between deﬂections.
e110 Fuster et al. JACC Vol. 57, No. 11, 2011 ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98remained unchanged (24). The median age of AF patients isabout 75 y. Approximately 70% are between 65 and 85 y old.The overall number of men and women with AF is aboutequal, but approximately 60% of AF patients over 75 y arefemale. Based on limited data, the age-adjusted risk ofdeveloping AF in blacks seems less than half that in whites(18,25,26). AF is less common among African-Americanthan Caucasian patients with heart failure (HF). In population-based studies, patients with no history ofcardiopulmonary disease account for fewer than 12% of allcases of AF (11,22,27,28). In some series, however, theobserved proportion of lone AF was over 30% (29,30). Figure 5. Incidence of atrial ﬁbrillation in 2 American epidemio- logical studies. Framingham indicates the Framingham Heart These differences may depend on selection bias when Study. Data are from Wolf PA, Abbott RD, Kannel WB. Atrialrecruiting patients seen in clinical practice compared with ﬁbrillation: a major contributor to stroke in the elderly. The Fra-population-based observations. In the Euro Heart Survey on mingham Study. Arch Intern Med 1987;147:1561– 4 (32). CHSAF (31), the prevalence of idiopathic AF amounted to 10%, indicates the Cardiovascular Health Study. Data are from Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factorswith an expected highest value of 15% in paroxysmal AF, for atrial ﬁbrillation in older adults. Circulation 1997;96:2455– 6114% in ﬁrst-detected AF, 10% in persistent AF, and only 4% (25); and Furberg CD, Psaty BM, Manolio TA, et al. Prevalencein permanent AF. Essential hypertension, ischemic heart of atrial ﬁbrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236 – 41 (22), and Farrell B, God-disease, HF (Table 2), valvular heart disease, and diabetes are win J, Richards S, et al. The United Kingdom transient isch-the most prominent conditions associated with AF (14). aemic attack (UK-TIA) aspirin trial: ﬁnal results. J Neurol Neuro- surg Psychiatry 1991;54:1044 –54 (46).4.2. IncidenceIn prospective studies, the incidence of AF increases from associated with a reduced incidence of AF in patients withless than 0.1% per year in those under 40 y old to exceed 1.5% hypertension (41,42), although this may be conﬁned to thoseper year in women and 2% in men older than 80 (Fig. 5) with left ventricular hypertrophy (LVH) (43– 45).(25,32,33). The age-adjusted incidence increased over a 30-yperiod in the Framingham Study (32), and this may have 4.3. Prognosisimplications for the future impact of AF (34). During 38 y of AF is associated with an increased long-term risk of strokefollow-up in the Framingham Study, 20.6% of men who devel- (47), HF, and all-cause mortality, especially in women (48).oped AF had HF at inclusion versus 3.2% of those without AF; The mortality rate of patients with AF is about double that ofthe corresponding incidences in women were 26.0% and 2.9% patients in normal sinus rhythm and linked to the severity of(35). In patients referred for treatment of HF, the 2- to 3-y underlying heart disease (20,23,33) (Fig. 6). About two-thirdsincidence of AF was 5% to 10% (25,36,37). The incidence of of the 3.7% mortality over 8.6 mo in the Etude en ActivitéAF may be lower in HF patients treated with angiotensin Libérale sur la Fibrillation Auriculaire Study (ALFA) wasinhibitors (38 – 40). Similarly, angiotensin inhibition may be attributed to cardiovascular causes (29). Table 3 shows a list of associated heart diseases in the population of the ALFATABLE 2. Prevalence of AF in Patients With Heart Failure as study (29).Reﬂected in Several Heart Failure TrialsPredominant Prevalence ofNYHA Class AF (%) StudyI 4 SOLVD–Prevention (1992)(14a)II-III 10 to 26 SOLVD–Treatment (1991) (14b) CHF-STAT (1995) (14c) MERIT-HF (1999) (14d) DIAMOND-CHF (1999) (501)II-IV 12 to 27 CHARM (2003) Val-HeFT (2003) (848)III-IV 20 to 29 Middlekauff (1991) (14e) Stevenson (1996) GESICA (1994) (14f)IV 50 CONSENSUS (1987) (14g) Figure 6. Relative risk of stroke and mortality in patients with AF indicates atrial ﬁbrillation; NYHA, New York Heart Association; SOLVD, atrial ﬁbrillation (AF) compared with patients without AF. SourceStudies Of Left Ventricular Dysfunction; CHF-STAT, Survival Trial of Antiarrhyth- data from the Framingham Heart Study (Kannel WB, Abbott RD,mic Therapy in Congestive Heart Failure; MERIT-HF, Metropolol CR/XL Ran- Savage DD, et al. Coronary heart disease and atrial ﬁbrillation:domized Intervention Trial in Congestive Heart Failure; DIAMOND-CHF, Danish the Framingham Study. Am Heart J 1983;106:389 –96) (23), the Regional Heart Study and the Whitehall study (Flegel KM, Shi-Investigations of Arrhythmia and Mortality on Dofetilide–Congestive Heart pley MJ, Rose G. Risk of stroke in non-rheumatic atrial ﬁbrilla-Failure; CHARM, Candesartan in Heart failure, Assessment of Reduction in tion), and the Manitoba study (Krahn AD, Manfreda J, Tate RB,Mortality and morbidity; Val-HeFT, Valsartan Heart Failure Trial; GESICA, Grupo et al. The natural history of atrial ﬁbrillation: incidence, risk fac-Estudio de la Sobrevida en la Insufﬁcienca Cardiaca en Argentina (V); and tors, and prognosis in the Manitoba Follow-Up Study. Am JCONSENSUS, Co-operative North Scandinavian Enalapril Survival Study. Med 1995;98:476 – 84) (33).
e112 Fuster et al. JACC Vol. 57, No. 11, 2011 ACC/AHA/ESC Practice Guidelines March 15, 2011:e101–98lation of glycogen granules, disruption of cell coupling at gap increase the extracellular matrix, especially during prolongedjunctions (67), and organelle aggregates (68). The concentra- periods of AF. Fibrosis is not the primary feature of AF-tion of membrane-bound glycoproteins that regulate cell-cell induced structural remodeling (95,96), although accumula-and cell-matrix interactions (disintegrin and metalloprotei- tion of extracellular matrix and ﬁbrosis are associated withnases) in human atrial myocardium has been reported to more pronounced myocytic changes once dilation occurs duedouble during AF. Increased disintegrin and metalloprotei- to AF or associated heart disease (90,97). These changesnase activity may contribute to atrial dilation in patients with closely resemble those in ventricular myocytes in the hiber-long-standing AF. nating myocardium associated with chronic ischemia (98). Atrial ﬁbrosis may be caused by genetic defects like lamin Among these features are an increase in cell size, perinuclearAC gene mutations (69). Other triggers of ﬁbrosis include glycogen accumulation, loss of sarcoplasmic reticulum andinﬂammation (70) as seen in cardiac sarcoidosis (71) and sarcomeres (myolysis). Changes in gap junction distributionautoimmune disorders (72). In one study, histological and expression are inconsistent (61,99), and may be lesschanges consistent with myocarditis were reported in 66% of important than ﬁbrosis or shortened refractoriness in promot-atrial biopsy specimens from patients with lone AF (62), but ing AF. Loss of sarcomeres and contractility seems to protectit is uncertain whether these inﬂammatory changes were a myocytes against the high metabolic stress associated withcause or consequence of AF. Autoimmune activity is sug- rapid rates. In fact, in the absence of other pathophysiologicalgested by high serum levels of antibodies against myosin factors, the high atrial rate typical of AF may cause ischemiaheavy chains in patients with paroxysmal AF who have no that affects myocytes more than the extracellular matrix andidentiﬁed heart disease (72). Apart from ﬁbrosis, atrial interstitial tissues.pathological ﬁndings in patients with AF include amyloidosis Aside from changes in atrial dimensions that occur over(73,74), hemochromatosis (75), and endomyocardial ﬁbrosis time, data on human atrial structural remodeling are limited(75,76). Fibrosis is also triggered by atrial dilation in any type (96,100) and difﬁcult to distinguish from degenerativeof heart disease associated with AF, including valvular changes related to aging and associated heart disease (96).disease, hypertension, HF, or coronary atherosclerosis (77). One study that compared atrial tissue specimens from patientsStretch activates several molecular pathways, including the with paroxysmal and persistent lone AF found degenerativerenin-angiotensin-aldosterone system (RAAS). Both angio- contraction bands in patients with either pattern of AF, whiletensin II and transforming growth factor-beta1 (TGF-beta1) myolysis and mitochondria hibernation were limited to thoseare upregulated in response to stretch, and these molecules with persistent AF. The activity of calpain I, a proteolyticinduce production of connective tissue growth factor (CTGF) enzyme activated in response to cytosolic calcium overload,(70). Atrial tissue from patients with persistent AF undergo- was upregulated in both groups and correlated with ioning open-heart surgery demonstrated increased amounts of channel protein and structural and electrical remodeling.extracellular signal-regulated kinase messenger RNA (ERK- Hence, calpain activation may link calcium overload to2-mRNA), and expression of angiotensin-converting enzyme cellular adaptation in patients with AF (341).(ACE) was increased 3-fold during persistent AF (78). Astudy of 250 patients with AF and an equal number of 5.1.2. Mechanisms of Atrial Fibrillationcontrols demonstrated the association of RAAS gene poly- The onset and maintenance of a tachyarrhythmia require bothmorphisms with this type of AF (79). an initiating event and an anatomical substrate. With respect Several RAAS pathways are activated in experimental to AF, the situation is often complex, and available data(78,80 – 84) as well as human AF (78,85), and ACE inhibition support a “focal” mechanism involving automaticity or mul-and angiotensin II receptor blockade had the potential to tiple reentrant wavelets. These mechanisms are not mutuallyprevent AF by reducing ﬁbrosis (84,86). exclusive and may at various times coexist in the same patient In experimental studies of HF, atrial dilation and interstitial (Fig. 7).ﬁbrosis facilitates sustained AF (86 –92). The regional elec- 184.108.40.206. AUTOMATIC FOCUS THEORYtrical silence (suggesting scar), voltage reduction, and con- A focal origin of AF is supported by experimental models ofduction slowing described in patients with HF (93) are similar aconitine and pacing-induced AF (102,103) in which theto changes in the atria that occur as a consequence of aging. arrhythmia persists only in isolated regions of atrial myocar- AF is associated with delayed interatrial conduction and dium. This theory received minimal attention until the im-dispersion of the atrial refractory period (94). Thus, AF seems portant observation that a focal source for AF could beto cause a variety of alterations in the atrial architecture and identiﬁed in humans and ablation of this source couldfunction that contribute to remodeling and perpetuation of the extinguish AF (104). While PVs are the most frequent sourcearrhythmia. Despite these pathological changes in the atria, of these rapidly atrial impulses, foci have also been found inhowever, isolation of the pulmonary veins (PVs) will prevent the superior vena cava, ligament of Marshall, left posteriorAF in many such patients with paroxysmal AF. free wall, crista terminalis, and coronary sinus (79,104 –110).220.127.116.11. PATHOLOGICAL CHANGES CAUSED BY In histological studies, cardiac muscle with preservedATRIAL FIBRILLATION electrical properties extends into the PV (106,111–116), andJust as atrial stretch may cause AF, AF can cause atrial the primacy of PVs as triggers of AF has prompted substan-dilation through loss of contractility and increased compli- tial research into the anatomical and EP properties of theseance (61). Stretch-related growth mechanisms and ﬁbrosis structures. Atrial tissue on the PV of patients with AF has
JACC Vol. 57, No. 11, 2011 Fuster et al. e113March 15, 2011:e101–98 ACC/AHA/ESC Practice Guidelines Figure 7. Posterior view of principal electro- physiological mechanisms of atrial ﬁbrillation. A, Focal activation. The initiating focus (indicated by the star) often lies within the region of the pulmonary veins. The resulting wavelets repre- sent ﬁbrillatory conduction, as in multiple-wavelet reentry. B, Multiple-wavelet reentry. Wavelets (indicated by arrows) randomly reenter tissue previously activated by the same or another wavelet. The routes the wavelets travel vary. Reproduced with permission from Konings KT, Kirchhof CJ, Smeets JR, et al. High-density mapping of electrically induced atrial ﬁbrillation in humans. Circulation 1994;89:1665– 80 (101). LA indicates left atrium; PV, pulmonary vein; ICV, inferior vena cava; SCV, superior vena cava; and RA, right atrium.shorter refractory periods than in control patients or other For many years, the multiple-wavelet hypothesis was theparts of the atria in patients with AF (117,118). The refractory dominant theory explaining the mechanism of AF, but theperiod is shorter in atrial tissue in the distal PV than at the data presented above and from experimental (127a) andPV-LA junction. Decremental conduction in PV is more clinical (127b,127c) mapping studies challenge this notion.frequent in AF patients than in controls, and AF is more Even so, a number of other observations support the impor-readily induced during pacing in the PV than in the LA. This tance of an abnormal atrial substrate in the maintenance ofheterogeneity of conduction may promote reentry and form a AF. For over 25 y, EP studies in humans have implicatedsubstrate for sustained AF (119). Programmed electrical atrial vulnerability in the pathogenesis of AF (128 –132). Instimulation in PV isolated by catheter ablation initiated one study of 43 patients without structural heart disease, 18 ofsustained pulmonary venous tachycardia, probably as a con- whom had paroxysmal AF, the coefﬁcient of dispersion ofsequence of reentry (120). Rapidly ﬁring atrial automatic foci atrial refractoriness was signiﬁcantly greater in the patientsmay be responsible for these PV triggers, with an anatomical with AF (128). Furthermore, in 16 of 18 patients with asubstrate for reentry vested within the PV. history of AF, the arrhythmia was induced with a single Whether the source for AF is an automatic focus or a extrastimulus, while a more aggressive pacing protocol wasmicroreentrant circuit, rapid local activation in the LA cannot required in 23 of 25 control patients without previouslyextend to the RA in an organized way. Experiments involving documented AF. In patients with idiopathic paroxysmal AF,acetylcholine-induced AF in Langendorf-perfused sheep widespread distribution of abnormal electrograms in the RAhearts demonstrated a dominant ﬁbrillation frequency in the predicted development of persistent AF, suggesting an abnor-LA with decreasing frequency as activation progressed to the mal substrate (132). In patients with persistent AF who hadRA. A similar phenomenon has been shown in patients with undergone conversion to sinus rhythm, there was signiﬁcantparoxysmal AF (121). Such variation in conduction leads to prolongation of intra-atrial conduction compared with adisorganized atrial activation, which could explain the ECG control group, especially among those who developed recur-appearance of a chaotic atrial rhythm (122). The existence of rent AF after cardioversion (130).triggers for AF does not negate the role of substrate modiﬁ- Patients with a history of paroxysmal AF, even those withcation. In some patients with persistent AF, disruption of the lone AF, have abnormal atrial refractoriness and conductionmuscular connections between the PV and the LA may compared with patients without AF. An abnormal signal-terminate the arrhythmia. In others, AF persists following averaged P-wave ECG reﬂects slowed intra-atrial conductionisolation of the supposed trigger but does not recur after and shorter wavelengths of reentrant impulses. The resultingcardioversion. Thus, in some patients with abnormal triggers, increase in wavelet density promotes the onset and mainte-sustained AF may depend on an appropriate anatomical nance of AF. Among patients with HF, prolongation of the Psubstrate. wave was more frequent in those prone to paroxysmal AF18.104.22.168. MULTIPLE-WAVELET HYPOTHESIS (133). In specimens of RA appendage tissue obtained fromThe multiple-wavelet hypothesis as the mechanism of reen- patients undergoing open-heart surgery, P-wave duration wastrant AF was advanced by Moe and colleagues (123), who correlated with amyloid deposition (73). Because many ofproposed that fractionation of wavefronts propagating these observations were made prior to the onset of clinicalthrough the atria results in self-perpetuating “daughter wave- AF, the ﬁndings cannot be ascribed to atrial remodeling thatlets.” In this model, the number of wavelets at any time occurs as a consequence of AF. Atrial refractoriness increasesdepends on the refractory period, mass, and conduction with age in both men and women, but concurrent age-relatedvelocity in different parts of the atria. A large atrial mass with ﬁbrosis lengthens effective intra-atrial conduction pathways.a short refractory period and delayed conduction increases the This, coupled with the shorter wavelengths of reentrantnumber of wavelets, favoring sustained AF. Simultaneous impulses, increases the likelihood that AF will developrecordings from multiple electrodes supported the multiple- (134,135). Nonuniform alterations of refractoriness and con-wavelet hypothesis in human subjects (127). duction throughout the atria may provide a milieu for the